Growing Number of Hospital NICUs Turning to Prolacta’s 100 Percent Human Milk-Based Nutrition for the Premature Infants in Their Care
Type: Press Releases
Topic(s): Clinical Studies on Prolact/Humavant CR Company Cost Savings / Cost Effectiveness
Prolacta Bioscience® to Provide Perspective on the Needs of Newborns With Heart Defects
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
Prolacta Bioscience Doubles Expiration Time and Simplifies Use of Prolact CR® Human Milk-Based Caloric Fortifier
Type: Press Releases
Topic(s): Company Healthcare Professionals Product
Steven D. Townsend, Ph.D., Wins the Ruth A. Lawrence Investigator Award for Research in Human Milk Science
Type: Press Releases
Topic(s): Healthcare Professionals
Prolacta Bioscience Celebrates Breastfeeding Awareness Month With Educational Video Series for Breastfeeding Mothers
Type: Press Releases
Topic(s):
Prolacta Bioscience Introduces Prolact+6 H2MF® in a New 15 mL Volume
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness Product
Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet Including a Specialty Fortifier in Term Infants Born with Single Ventricle Congenital Heart Defects
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
New Analysis Published in the Journal Breastfeeding Medicine Finds Additional Clinically Significant Benefits From an Exclusive Human Milk Diet in the NICU
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Cost Savings / Cost Effectiveness Necrotizing Entercolitis (NEC) Product Total Parenteral Nutrition (TPN) Use
Starting 100 Percent Human Milk-Based Fortifier Early Is Associated With Improved Growth in Extremely Premature Infants, According to an Independent Study
Type: Press Releases
Topic(s): Growth Healthcare Professionals Necrotizing Entercolitis (NEC) Neurodevelopmental Outcomes
